Nordic Issuing

Ongoing case

RhoVac AB

Back to all cases

RhoVac AB

15 Jun - 15 Jul 2022Conversion of convertibles

RhoVac is a pharmaceutical company dedicated to immuno-oncology, signifying that the body’s own immune system is stimulated to identify and destroy cancer cells. The primary focus of RhoVac is to develop a cancer therapy that targets metastatic cells to prevent cancer recurrence and progression after primary tumour therapy. RhoVac was founded as a private company in Denmark 2007. In the following years the first steps in terms of development of the drug candidate, RV001, were taken. In 2015 the Swedish RhoVac AB, now headquarters, was founded, and in 2016 the company was listed on “Spotlight Stock Market”.

Read more on the company's website

The offer in summary

Subscription period: 15 June - 15 July 2022

Price per share: SEK 40.00

Trading with convertibles: Until 13 July 2022

Emission volume: Maximum of about mSEK 25

Payment day: 15 July 2022

Marketplace: Spotlight Stock Market

Financial advisor: Sedermera Corporate Finance


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.